Resource: Studies on Myocarditis and COVID-19 Vaccination

This page contains research links on COVID-19 vaccination and myocarditis, a type of heart inflammation, and/or pericarditis, a related condition.

March 2021

March 20th, Spain Case report of a 39-year-old male doctor who developed myocarditis after receiving his first dose of Pfizer vaccine. COVID-19 testing came back negative. Researchers have concluded: “It seems reasonable to associate the clinical picture developed by this patient with an adverse reaction to the BNT162b2 vaccine against COVID-19.”
March 31st, Italy Report of a healthy 56-year-old man who developed myocarditis after receiving the second dose of Pfizer’s vaccine.

April 2021

Base (pre-pandemic) rates of myocarditis and other countries presented on April 17 (later peer-reviewed).
On April 29, Israel, two patients developed pericarditis following COVID-19 vaccination.

May 2021

May 18: A 24-year-old man in the United States developed myocarditis after receiving COVID-19 vaccination. Doctors: “Our case report raises concern that myocarditis is a rare side effect of COVID-19 vaccine.”

May 28 Israel Case series of six male patients with myocarditis following COVID-19 vaccination who had no evidence of COVID-19 or other causes.
On May 31, Israel, three young males were diagnosed with postvaccination myocarditis.
June 2021:
On June 4, a series of seven previously healthy males aged 19 or younger developed myocarditis following COVID-19 vaccination in the United States. COVID-19 and MIS-C were ruled out by doctors. Researchers claim that the symptoms resolved “rapidly.”
An accompanying editorial from the American Academy of Pediatrics states: “Although the authors are quick to point out that a causal relationship between vaccination and myocarditis has not been established, the temporal association of these cases with vaccination as well as the striking similarity in the clinical and laboratory presentations raise the possibility for such a relationship.”

Case report of a 30-year-old man with myocarditis following COVID-19 vaccination, with other causes ruled out.
On June 10, four patients, including two students, were diagnosed with myocarditis shortly after receiving COVID-19 vaccination.
Advertisement – Continue reading below
On June 14, a 24-year-old man developed myocarditis after receiving his second Pfizer dose. Virus tests came back negative.
Six previously healthy males with no signs of infectious illness who developed chest pain four days after their second shot on June 16 in the United States. Myocarditis was confirmed by imaging.
Following COVID-19 vaccination, four myocarditis patients were treated in the United States, two of whom did not have COVID-19.
The United States, Italy, and so on. Eight “otherwise healthy males” as young as 21 were diagnosed with myocarditis following vaccination with Pfizer or Moderna.
Seven patients in the United States develop myocarditis following COVID-19 vaccination. Some had previously attended COVID-19.
A previously healthy 52-year-old man in the United States developed myocarditis after receiving a second dose of Moderna’s vaccine.
A previously healthy 16-year-old male was hospitalized with myopericarditis after receiving a second dose of Pfizer’s vaccine.
A 37-year-old man in Qatar developed myocarditis after receiving a second dose of Pfizer’s vaccine. Doctors: “Vaccine-induced myocarditis is the most likely diagnosis in our patient.”
On June 17, two previously healthy young adults were hospitalized with myocarditis following a Moderna vaccination.
On June 22, a 17-year-old male from the United States developed MRI-confirmed myocarditis after receiving his second Pfizer dose. According to the researchers: “This case highlights the possibility that the COVID-19 mRNA vaccine may trigger recurrent acute myocarditis in children and adolescents who have had a previous episode of acute myocarditis.”
The Pfizer and Moderna vaccines are “significantly associated” with the inflammation, according to a study of 214 reports of myocarditis after COVID-19 vaccination.
On June 28, two adolescent males in the United States developed myocarditis as a result of a Pfizer vaccination.
June 29th, Italy Case report of a previously healthy 20-year-old male developing myocarditis following Pfizer vaccination and, previously, COVID-19.
Between February 1 and April 30, 2021, four patients at Duke University Medical Center developed myocarditis following COVID-19 vaccination. Researchers have concluded: “It is possible that these 4 cases of acute myocarditis represent a rare, potential adverse event linked to mRNA COVID-19 vaccination.”
US military series of 23 people with myocarditis after receiving an mRNA COVID-19 vaccine, including 22 previously healthy military members. Seven people are still suffering from symptoms.
In an editorial, the CDC stated, “The striking clinical similarities in the presentations of these patients, their recent vaccination with an mRNA-based COVID-19 vaccine, and the lack of any alternative etiologies for acute myocarditis suggest an association with immunization.”
July 2021:
Spain Case report of a patient with postvaccination myocarditis.
Thirteen patients aged 12 to 17 were diagnosed with myopericarditis within one week of receiving the second dose of Pfizer’s vaccine on July 3. CMR (cardiovascular magnetic resonance) was used to image the patient. Researchers wrote: “Although the symptoms resolved rapidly in all patients, their CMR findings indicate the potential for myocardial fibrosis and unknown long-term impact.”
A 67-year-old man in the United States experienced heart failure after receiving a second dose of Moderna’s vaccine. COVID-19 and influenza testing came back negative.
On July 6, the Centers for Disease Control and Prevention (CDC) reported 484 cases of myocarditis in people under the age of 30. From May 1 to June 11, 323 cases were confirmed as probable or confirmed by investigators using the Vaccine Adverse Event Reporting System (VAERS). Doctors: “Follow-up is ongoing to identify and understand longer-term outcomes after myocarditis occurring after COVID-19 vaccination.”
On July 10, a 22-year-old man from Korea died seven hours after experiencing chest pain five days after receiving his first Pfizer dose. Doctors: “The primary cause of death was determined to be myocarditis, causally-associated with the BNT162b2 vaccine.”
US, etc. A 70-year-old woman developed myocarditis after receiving a Johnson & Johnson vaccination.
Case report meta-analysis published on July 12 in the United States.
On July 14, a 34-year-old previously healthy man was hospitalized after receiving his second dose of Moderna’s vaccine. Heart failure was one of the symptoms. After nine days, he was released.
Report of a 29-year-old man who developed recurrent acute myocarditis after receiving the first dose of Moderna’s vaccine on July 16, Italy.
Cross-sectional study of 29 published cases of acute myopericarditis following mRNA COVID-19 vaccination, published July 18 in the United States.
In early 2021, five patients with postvaccination myocarditis will undergo cardiac MRI imaging in the United States on July 20.
On July 24, Italy, a 24-year-old nurse developed myocarditis after receiving a second dose of Pfizer’s vaccine. COVID-19 and other viruses were ruled out by tests. After one week, he was released.
A previously healthy 29-year-old female presented to the emergency room on July 23 with perimyocarditis and multi-organ failure. The authors of the study: “Most of the cases reported by the CDC had an uncomplicated hospital outcome and recovered fully unlike our patient who became very sick. This points to a possibility of increased reactogenicity in some patients due to COVID-19 vaccination”
July 25th, Italy Case report of a 21-year-old male health care worker who developed myocarditis after receiving the second dose of Pfizer’s vaccine.
July 26: In the United States, previously healthy young males were hospitalized with myocarditis after receiving a second Pfizer dose.
Between January 1 and May 20, 2021, a query of a local health care database for myopericarditis patients aged 16 to 25 identifies eight patients with myocarditis within eight days of vaccination.
Cardiac MRIs on 15 of 16 children with myopericarditis after COVID-19 vaccination in the United States returned abnormal results on July 30. Researchers have concluded: “The long-term impact of myopericardial inflammation after COVID-19 mRNA vaccine, especially in those with extensive myocardial involvement on CMR, remains unknown and needs to be systematically evaluated.”
A review of 14 reports of deaths following vaccination in the United States revealed that one was caused by heart failure, a symptom of myocarditis. Six had unknown causes or were awaiting further documentation.
Australia’s health authorities detail 50 reports of suspected myocarditis and/or pericarditis following COVID-19 vaccination on July 31.
A 21-year-old man from Poland was hospitalized with myocarditis after receiving his first dose of Pfizer vaccination.
Three patients in Germany developed myocarditis after receiving COVID-19 vaccination. Researchers have concluded: “Regarding current discussions addressing the risk-benefit ratio of COVID-19 vaccination of children and teenagers, vaccination-associated adverse effects—including autoimmune myocarditis—need to be considered carefully, since young people are at a very low risk for severe COVID-19 infection even without vaccination.”
August 20, 2021:
Aug. 2 Italy Report of a 56-year-old man who developed myocarditis after receiving his first dose of Pfizer’s vaccine and four months after contracting COVID-19. Researchers have concluded: “At the present time the benefits of Covid-19 vaccination significantly exceed possible risks.”
On August 3, a previously healthy 15-year-old boy was hospitalized for seven days with myocarditis following the second dose of a Pfizer vaccine.
On August 4, a 44-year-old man was hospitalized after receiving his second dose of Moderna vaccine.
A previously healthy 22-year-old man from the United States was hospitalized three days after receiving the first dose of Moderna’s vaccine.
A review of electronic medical records from 40 hospitals in the United States uncovered 57 cases of vaccine-related myocarditis or pericarditis. As of the most recent follow-up, fourteen problems had not been fully resolved.
South Korea, August 6: A 24-year-old male was hospitalized with acute myocarditis after receiving a second dose of Pfizer’s vaccine. Researchers have concluded: “Although severe serious acute myocarditis following COVID-19 vaccination has been rarely reported, rapid surveillance such as cardiac markers, electrocardiography, or cardiac imaging should be required for its early diagnosis in patients with chest discomfort within one week following vaccination.”
The Canada Framework for Health Care Providers to Assess Suspected and Confirmed Cases of Myocarditis Following COVID-19 Vaccination was released on August 8th.
Four patients, aged 20 to 30, developed myocarditis four days after receiving mRNA COVID-19 vaccines.
Germany: A 28-year-old man was hospitalized nine days after receiving a Pfizer vaccine. Non-vaccine causes have been ruled out.
August 10 (CDC): A new risk-benefit analysis compares benefits (numbers of COVID-19 cases and severe outcomes avoided) to risks (only myocarditis). For 18 to 29-year-old males, per million second doses administered, 300 estimated hospitalizations and three deaths were avoided over the next 120 days, compared to 22 to 27 cases of myocarditis caused.
Between May 1 and July 15, 2021, 15 children under the age of 19 were admitted to Boston Children’s Hospital with myocarditis after receiving a Pfizer dose. Four patients had ongoing symptoms.
A 33-year-old neurologist from India developed myocarditis symptoms after the first COVAXIN dose.
Aug. 16 Hong Kong recommends one week of rest after COVID-19 vaccination, stating that the benefits outweigh the risks.
A 27-year-old male from the United States was hospitalized with myocarditis after receiving his second dose of Pfizer vaccine.
A previously healthy 33-year-old man developed myocarditis after receiving the Johnson & Johnson vaccine.
On August 17, two patients in the United States were hospitalized following a Pfizer vaccination. One person died as a result of cardiac arrest and multi-organ failure. The autopsy request was turned down by the family. Researchers write: “These cases identify the need for awareness of a potential, albeit extremely rare, link of BNT162b2 mRNA COVID-19 vaccination associated with fulminant myocarditis.”
Aug 18 Case report from the United States of two patients hospitalized with myocarditis following COVID-19 vaccination. One person died. There were no non-vaccine causes identified.
Pfizer’s vaccine causes myopericarditis in Hong Kong mice.
On August 19, Germany’s Paul-Ehrlich-Institut reports 393 cases of pericarditis or myocarditis following Pfizer vaccination and 49 cases following Moderna vaccination.
Data from Israel’s largest health-care organization show that vaccination is strongly linked to an increased risk of myocarditis.
Israel Eight patients were hospitalized with suspected myocarditis after receiving a second Pfizer dose between February and April 2021.
Aug. 27 Italy advises against COVID-19 vaccination in patients who have had elevated troponin levels for at least six months, as well as in patients who have had myocarditis after their first dose.
September 20, 2021
According to a September 1 China analysis of published trials and VAERS reports, over 1,600 reports of postvaccination myocarditis and pericarditis have been filed.
Italy, the United States, and so on. According to published reports, all patients were discharged, with the exception of several patients who died.
According to the Centers for Disease Control and Prevention, 565.9 cases of postvaccination myocarditis are reported every million person-years among males aged 12 to 39.
Sept. 4 Israeli military series of seven male patients who developed myocarditis after receiving a second dose of Pfizer’s vaccine.
On September 6, a previously healthy 40-year-old man was admitted to the hospital with biopsy-confirmed myocarditis following the first dose of COVID-19 vaccination. After four days, he was released. An eight-day follow-up cardiac MRI revealed persistent issues.
A 62-year-old woman died of myocarditis after receiving a Johnson & Johnson vaccine on September 7. Researchers write: “This case suggests a potential relationship between the viral vector COVID-19 vaccine and the patient’s lymphohistiocytic myocarditis resulting in severe biventricular cardiomyopathy and death.”
The rates of cardiac adverse events following COVID-19 vaccination were higher than the risk of COVID-19 hospitalization, according to a September 8 US (later peer-reviewed) VAERS review for adolescents aged 12 to 17.
On September 9, five male patients in the United States developed acute myocarditis within 72 hours of receiving an mRNA vaccine. COVID-19 testing came back negative. Other viruses were ruled out in some cases.
Italy: A 45-year-old previously healthy male developed myocarditis and shock following COVID-19 vaccination.
On September 11, a 66-year-old man in the United States began experiencing symptoms three months after receiving his second dose of Pfizer’s vaccine. Within 48 hours, the issue was resolved. Researchers concluded: “Although causality could not be established, there was no other identifiable cause to explain the occurrence of acute myocarditis. The present case report provides new evidence regarding possible subacute to late-onset of myocarditis post-COVID-19 vaccine.”
September 14th, US Case series of six previously healthy men who developed severe chest pain and myocarditis four days after receiving a second dose of mRNA vaccination.
Patients in the United States were hospitalized with myocarditis after receiving mRNA vaccines. Two had prior COVID-19 experience.
11 patients in the United States developed myocarditis after receiving COVID-19 vaccination.
Data from a health-care organization in Israel show 48 cases of myocarditis or pericarditis following COVID-19 vaccination, compared to 24 in the unvaccinated.
On September 18, a previously healthy 20-year-old man developed myocarditis 12 hours after receiving his first dose of Moderna’s vaccine.
On September 20, two male teenagers in the United States developed acute myopericarditis after receiving Pfizer’s vaccine. One child was admitted to the pediatric intensive care unit.
Two young males in the United States were hospitalized within days of receiving mRNA vaccination. COVID-19 testing was negative, and there was no history of COVID-19.
On September 21, Japan, two men developed myocarditis following Moderna vaccination.
According to a US Editorial, while VAERS “is subject to bias,” “a clear signal for vaccine-associated myocarditis has emerged.”
Case report of a previously healthy 29-year-old man who was hospitalized several days after receiving a second dose of Pfizer’s vaccine on September 22.
Three days after his first Pfizer dose, a 16-year-old male presented with “severe, stabbing chest pain” and fever. After a few days, he was released. Doctors: “Given the relatively small clinical benefit of a second dose of vaccine for someone of his demographic compared with the potential risk of myocarditis recurrence, he has been advised against a further dose at this stage.”
Ireland Case report of a 66-year-old man who developed myocarditis after receiving COVID-19 vaccination.
Sept. 26: In the United States, a 17-year-old male who was otherwise healthy developed myocarditis after receiving Pfizer’s vaccine.
On September 30, a previously healthy 16-year-old female was hospitalized after receiving her second dose of Pfizer’s vaccine.
Germany Postmortem examinations of 18 vaccinated individuals, including full autopsies and other procedures. After receiving a Pfizer dose, one person, a 65-year-old man, died of myocarditis.
Japan A previously healthy 49-year-old man was hospitalized for 15 days with myocarditis after receiving the second dose of Pfizer’s vaccine.
Report from Iran of a 70-year-old man who developed vaccine-induced myocarditis after receiving his first AstraZeneca shot. Scientists state: “This case … confirms that myocarditis is a complication of COVID-19 vaccine.”
October 20, 2021:
On October 1, an otherwise healthy 54-year-old woman developed pericarditis after receiving her second dose of Pfizer vaccination.
Seven patients (aged 16 to 18) from three pediatric medical centers in Israel were hospitalized with myocarditis after receiving Pfizer’s vaccine.
South Korea Case report of a previously healthy 29-year-old male army soldier who developed chest pain after receiving the second dose of Pfizer’s vaccine.
On October 2, a 22-year-old female was hospitalized after receiving her second Moderna vaccine dose.
On October 3, Japan, a 20-year-old woman was diagnosed with biopsy-confirmed acute myocarditis following the second dose of Moderna’s vaccine.
Oct. 4 (HealthDay News) — A study of Kaiser Permanente Southern California members aged 18 and up who received at least one dose of an mRNA shot between December 14, 2020, and July 20, 2021, and were hospitalized within 10 days with a discharge diagnosis of myocarditis found 15 cases.
According to a US Editorial, identifying cases of postvaccination myocarditis “does not change clinical decision-making.”
Oct. 6 Israel: A review of myocarditis cases appearing in nationwide surveillance through May 31, 2021, identifies 182 as having been triggered by COVID-19 vaccination. A 22-year-old patient died.
Israel Case study of people aged 16 and up who were vaccinated between December 20, 2020, and May 24, 2021 and enrolled in Clalit Health Services.
Oct. 11 Switzerland According to a position paper published by the Swiss Society of Paediatric Cardiology, the “very low risk” of myocarditis and pericarditis “should not discourage vaccination.”
Oct. 12 Spain A 28-year-old man without COVID-19 was admitted to the hospital with myocarditis two weeks after receiving his second Pfizer dose. Two months later, echocardiography revealed abnormalities.
Oct. 15 Jordan, US Analysis of VAERS reports, including a recommendation to extend the time between the first and second doses.
A case series of elderly people in the United Kingdom with “probable vaccination-induced cardiac conduction disturbances” after receiving COVID-19 vaccination.
Oct. 18, Saudi Arabia A previously healthy 18-year-old was hospitalized after receiving a second dose of Pfizer’s vaccine.
On October 19, France, a 19-year-old man was hospitalized three days after receiving Pfizer’s booster. cMRI confirmed acute myocarditis.
Young males in the United States who developed myocarditis after receiving an mRNA shot. All were discharged with beta blockers and restrictions on exercise.
Oct. 21 Brazil Case report of a 47-year-old man who received two doses of a COVID-19 vaccine, developed COVID-19 reinfection, and died from myocarditis.
A 32-year-old man in the United States was hospitalized after receiving Moderna’s vaccine. COVID-19 was found to be present.
A previously healthy 18-year-old man in the United States developed pericarditis after taking his first Pfizer dose.
Myocarditis after mRNA vaccination is rare, according to a narrative review published on October 26 in France.
Oct. 27 US Some patients with myocarditis following COVID-19 vaccination experienced persistent symptoms after being discharged from the hospital.
Stratification of Israel in previous research. Shows five cases of myocarditis in vaccinated males aged 16 to 19, and none in unvaccinated males; 18 in vaccinated males aged 16 to 39, and three in unvaccinated males.
An observational study of VAERS data by the CDC (later peer-reviewed) uncovers 4,496 reports of death. There were four deaths from myocarditis, none of which had a death certificate or an autopsy.
A VAERS review conducted in the United States and China on October 28 discovered an increased risk of myocarditis and pericarditis following mRNA vaccination.
Italy A single case of pericarditis was discovered in a single-center study.
Denmark Case report of a previously healthy 17-year-old male developing multisystem inflammatory syndrome after a second Pfizer dose.
On October 29, a previously healthy 38-year-old female in South Korea suffered a heart attack following COVID-19 vaccination. Researchers wrote, “Contrary to most previous reports, the present case demonstrated that the clinical course of the COVID-19 vaccination-related myocarditis is not always benign.”
Greece Case series involving two patients with “cardiac tamponade necessitating emergent pericardial decompression” following COVID-19 vaccination.
Oct. 30: Cardiac MRI imaging in the United Kingdom, including a patient with acute myocarditis following mRNA vaccination.
Switzerland Seventeen patients with myocarditis after COVID-19 mRNA vaccination present to a single center between March and July 2021. Thirteen patients had recovered or were on their way to recovery at the time of discharge.
November 20, 2021:
Case report from the United States of a previously healthy 19-year-old who developed severe chest pain three days after receiving a second dose of an mRNA shot. A follow-up cardiac MRI revealed a minor abnormality.
Italy A previously healthy 20-year-old male was admitted to the hospital two days after receiving the second dose of Pfizer’s vaccine.
According to the Italian Society of Cardiology, the temporal relationship between myocarditis and COVID-19 vaccination “is not proof of causality, and only dedicated studies will be able to clarify this aspect.”
Nov. 1 England Risk-benefit analysis based on the CDC method. Vaccinating 12- to 17-year-olds is expected to save up to 4,430 hospital admissions and 36 deaths over the course of 16 weeks, compared to causing 160 cases of myocarditis/pericarditis.
Case report from the United States of an adolescent who presented to the emergency room with chest pain and tachycardia after receiving a Pfizer vaccination.
In the United States, a retrospective study of patients under the age of 21 diagnosed with COVID-19 vaccine-associated myocarditis identified 63 patients with a mean age of 15.6 years. A total of 54 patients were followed up on, and all but seven had their symptoms resolved. At the follow-up echocardiogram, 20% of the 60 patients had abnormal findings.
Denmark finds 15 cases among 12- to 17-year-olds in a nationwide study from May 15 to September 15, 2021. Researchers have found: “The incidence of myopericarditis after COVID-19 vaccination among males appears higher than reports from the United States.”
Nov. 3 Germany Case report of a 60-year-old man who was hospitalized approximately 24 hours after receiving the second dose of Moderna’s vaccine.
A systematic review of cases in the United States from July 17, 2021, reveals that myocarditis is most commonly seen in young males within a few days of receiving a second dose. Falsely claims that all patients recovered.
A case series at the Mayo Clinic in the United States reveals seven cases of vaccine-associated myocarditis.
Cardiac MRIs were performed on patients with postvaccination myocarditis on November 5. Researchers report: “CMR imaging findings are mild and consistent with ‘classical myocarditis’. The short-term clinical course and outcomes were favourable.”
Nov. 6 Japan Case report of a previously healthy 25-year-old man who was hospitalized three days after receiving Moderna’s vaccine for myocarditis.
Nov. 8 France Case report of two young males who developed myocarditis after receiving a second mRNA shot.
Singapore case report of a 53-year-old man who developed myocarditis after receiving COVID-19 vaccination.
10 November, Italy Comment on the use of cardiac MRI in the evaluation of patients with suspected myocarditis.
On November 11th, eight patients aged 15 to 17 were admitted to Nicklaus Children’s Hospital after receiving Pfizer’s vaccine.
Nov. 15: In the United States, four patients developed myocarditis-like illness after receiving mRNA COVID-19 vaccination, one of whom developed heart failure.
The criteria for diagnosis in the United States were reviewed on November 16th.
Three previously healthy young adolescents in the United States were hospitalized with confirmed myocarditis following Pfizer vaccination.
On November 17, Poland, a case series describing imaging of myocarditis patients following COVID-19 vaccination was published.
A November 18 editorial in the United States urges health-care professionals to put pressure on parents to get their children vaccinated. According to the study, postvaccination myocarditis “has been relatively mild and self-limited.”
Germany A 16-year-old boy develops myocarditis following mRNA vaccination.
Myocarditis findings on cardiac imaging in Canada.
Myocarditis “may be associated” with COVID-19 vaccination, according to Canada Review.
Singapore, November 19: A review of cardiac manifestations following COVID-19 vaccination.
Case report from South Korea of a 24-year-old patient who developed pericarditis after receiving COVID-19 vaccination.
Trends in cardiology consultations for suspected myocarditis after COVID-19 vaccination, Nov. 23, Germany and the United States. Researchers have concluded that “CMR remains important to rule out vaccine-associated myocardial injury.”
On November 24, Portugal reported a 39-year-old male with perimyocarditis following COVID-19 vaccination.
The article discusses cases of postvaccination myocarditis and calls for prospective studies “to better assess the risk-benefit ratios in different groups.”
Data from France show a higher number of myocarditis cases after second doses than after first doses.
Pakistan, Brazil, and Afghanistan: All patients who present with chest pain and other related symptoms following COVID-19 vaccination should be considered to have myocarditis, according to researchers.
Nov. 27 Japan A 27-year-old man and a 37-year-old man were hospitalized with suspected vaccine-related myocarditis following COVID-19 vaccination.
Nov. 28 – A study at Beth Israel Deaconess Medical Center in Boston found that vaccinated patients had a higher incidence than the control group.
The China Cohort study, conducted in Hong Kong, discovered 18.5 cases of myocarditis per 100,000 doses in 12- to 17-year-olds.
Singapore, Nov. 29 – Singapore military personnel were vaccinated up to July 24, 2021, with 64,661 receiving one or more doses. Three men aged 18 to 21 were diagnosed with myocarditis or pericarditis.
On November 30, Australia received a report of myocarditis following COVID-19 vaccination.
A 38-year-old man in the United States developed myocarditis after receiving the first dose of Moderna’s vaccine.
December 20, 2021:
Dec. 1 Poland Three previously healthy males aged 17 were hospitalized with sudden chest pain after receiving a Pfizer dose. COVID-19 and other viruses were found to be absent in all of them. Doctors: “Based on the clinical presentation, a diagnosis of myocarditis associated with COVID-19 vaccination was made.”
A 22-year-old woman from South Korea who developed myocarditis and other complications after receiving AstraZeneca’s vaccine tested negative for COVID-19. MIS-A was eventually diagnosed. Despite residual muscle weakness, he was discharged after 74 days. Study: “Vaccine-associated MIS-C may become more common as more children receive SARS-CoV-2 vaccination.”
In the United States, a review of records from the metro Detroit health care system reveals six cases of myocarditis, one with two or more vaccine doses and five with one or zero vaccine doses.
Case report of a previously healthy 23-year-old man hospitalized with myocarditis after receiving a second dose of Pfizer’s vaccine on December 2, Japan.
Dec. 3 France A retrospective study of reported cases concludes that the occurrence is “very rare” and does not jeopardize the risk-benefit balance.
Four days after receiving the first Moderna vaccine, a 29-year-old previously healthy man was hospitalized with acute myocarditis.
Report from Japan of a 19-year-old woman who experienced chest pain after receiving her second dose of COVID-19 vaccination.
A retrospective study of 26 pediatric medical centers in the United States found 145 patients under the age of 21 with suspected myocarditis within 30 days of receiving COVID-19 vaccination. There are 26 patients in intensive care. The authors of the study: “Although this case series cannot determine causality of suspected myocarditis from COVID-19 vaccination, the number of cases of suspected myocarditis within a short time frame after COVID-19 vaccination would be unlikely to be secondary to chance alone.”
France Hypothesis of Postvaccination Myocarditis Mechanisms.
On December 9, Bahrain, a previously healthy 24-year-old male was hospitalized five days after receiving a Pfizer vaccine. All viral serologies came back negative.
Japan Case report of a 20-year-old man who previously had myopericarditis from influenza and then experienced another event after receiving Moderna vaccination.
According to the US Search for Cardiovascular Events Following Vaccination, which found 2,785 cases of myocarditis or pericarditis reported to VAERS, “the mRNA vaccine platform likely does not increase the probability of myocarditis or pericarditis.”
The study found 746 cases of postvaccination myocarditis or pericarditis, compared to 161 after a positive COVID-19 test, and 61 deaths from myocarditis after vaccination, versus zero after a positive test.
Dec. 15 Italy A search for studies that looked at postvaccine deaths turned up 38 cases, 14 of which were related to the mRNA vaccine. Four patients had myocarditis.
Sixty-nine myocarditis or pericarditis cases were reported in Denmark on December 16th, with some patients dying or having heart failure. People who had previously tested positive for COVID-19 or had myocarditis were excluded.
According to a literature search conducted in Iran on December 17, myocarditis/myopericarditis and pericarditis were the most common adverse events among the 243 reported cardiac complications following mRNA COVID-19 vaccination. Large-scale observational studies are advised.
Dec. 21 South Korea A review of safety monitoring reveals one death from post-vaccination myocarditis.
Another literature search finds most patients to be male, claims all patients had a favorable course, but excludes death reports.
According to a survey sent to 107 pediatric cardiologists and infectious disease specialists in the United States, there is “marked variability in the diagnosis and management of” postvaccination myocarditis.
South Korea, December 24 – A nationwide retrospective study of high school seniors who received the Pfizer vaccine found a rate of myocarditis and/or pericarditis of 1.8 per 100,000 in first-dose recipients and 4.3 per 100,000 in second-dose recipients.
On December 25, Japan, a 53-year-old man was hospitalized after receiving a Pfizer vaccine.
Cohort study of patients who received at least one dose of an mRNA vaccine between December 2020 and October 2021 estimates risk among males aged 12 to 39 as 195.4 cases of myopericarditis per million second doses administered (later peer-reviewed). Researchers report: “We identified additional valid cases of myopericarditis following an mRNA vaccination that would be missed by the [Vaccine Safety Datalink’s] search algorithm.”
December 29th, Qatar, United States Literature review of postvaccination cardiovascular events.
Dec. 30 In the United States, 67 patients with myocarditis were admitted to Intermountain Healthcare between December 15, 2020, and June 15, 2021, with 21 having a recent COVID-19 vaccination. One person died.
Morocco Case report of a 14-year-old boy who experienced shock after receiving a Pfizer vaccine. After seven days, I was released. Doctors: “Given the seriousness of this disease, which can be fatal in its fulminant form, further research on the causal links between myocarditis and mRNA type COVID-19 vaccination is needed, especially in view of the large number of cases reported.”
January 20, 2022:
New Zealand, for example, on January 3rd. A 57-year-old woman died from myocarditis after receiving her first dose of Pfizer’s vaccine. Non-vaccine causes have been ruled out.
A previously healthy 20-year-old man from Japan was hospitalized with chest pain after receiving his second Moderna dose.
5 January, Japan A previously healthy 26-year-old man was admitted to the hospital with chest pain following COVID-19 vaccination. Later discharged, but took a leave of absence due to depression. Doctors: “The patient was a medical professional and was well aware that myocarditis can be fatal in severe cases, which may have been traumatic and led to depressive state. It is a priority to provide psychological support for the post-traumatic stress disorder-like depression which can occur as an adverse complication of the vaccine.”
On January 6, Turkey, patients with postvaccination myocarditis were evaluated.
On January 7, a previously healthy 24-year-old male developed myocarditis after receiving Pfizer’s second dose.
A 40-year-old man in the United States reported chest pain and dyspnea three days after receiving his first dose of Pfizer’s vaccine.
Jan. 9 Germany: Two doses of Moderna’s vaccine resulted in myocarditis in a young male firefighter. Both were released with exercise restrictions.
On January 10, a previously healthy 80-year-old woman was admitted to the hospital with severe myocarditis after receiving Pfizer’s vaccination.
Three cases of postvaccination myocarditis were reported in India on January 11th.
Report of a 59-year-old male found unresponsive hours after receiving his third dose of an mRNA shot on January 12 in the United States and Pakistan. The COVID-19 test was negative, and the other viral infection panel was “nonsignificant.” The patient had been revived and was still hospitalized when the case report was submitted. Doctors: “We believe the cardiac arrest was most likely secondary to the COVID-19 booster vaccination.”
A 59-year-old man in Italy developed myocarditis following a Pfizer vaccination.
Taiwan A 94-year-old man developed myocarditis after receiving an AstraZeneca vaccination.
On January 13, Qatar received a report of acute pericarditis following a booster shot.
Jan. 17, Spain A 24-year-old man was hospitalized with myocarditis after receiving a second Pfizer dose.
A previously healthy 49-year-old man developed pericarditis after receiving his second Moderna dose.
Jan. 18: A case series of young men hospitalized following mRNA vaccination in the United States.
Estimated benefits of extending the time between primary series doses in the United Kingdom.
Case report from Japan involving heart failure.
Jan. 19 Singapore Between Feb. 1, 2021, and June 30, 2021, none of the 34 deaths occurred within 72 hours of receiving a COVID-19 vaccine.
Spain, January 21st, meta-analysis of myocarditis following COVID-19 vaccination.
Jan. 22 Italy Six patients experienced cardiac involvement after receiving their second mRNA dose between August and September 2021.
A 57-year-old woman and a 63-year-old man were hospitalized on January 24 in China after receiving mRNA vaccines.
Case report from Australia of a 20-year-old man who developed symptoms 12 hours after receiving his second Pfizer dose.
The CDC identified 1,991 VAERS myocarditis reports for people aged 12 and older on January 25, with 1,626 meeting the CDC case definition. Males aged 16 or 17 had the highest rates after the second dose, at 105.9 per million Pfizer doses. Underreporting is expected, as has been the case with VAERS in the past.
Pfizer vaccination increases the risk of carditis in a Hong Kong case-control study.
A 14-year-old previously healthy male developed myopericarditis after receiving the second dose of an mRNA vaccine on January 27 in Turkey.
Greece Case report of a 56-year-old doctor who developed symptoms “mimicking a heart attack” a few days after receiving Pfizer’s second dose.
On January 28, 2010, a case series of ten people with COVID-19 vaccine-related myocarditis was confirmed by cardiac MRI in Canada.
The US reviewed 40 case reports on January 30.
According to the Iran Review, the most common symptom is chest pain.
February 20, 2022
On February 1, Iran, a 29-year-old man was hospitalized with myocarditis after receiving Russia’s Sputnik V vaccine.
Four patients in Israel developed myocarditis after receiving the third dose of Pfizer’s vaccine.
Norway, for example. Clinical presentation and management are reviewed.
On February 2, Turkey reported a 17-year-old with myocarditis following a Pfizer vaccination.
Two deaths and seven intensive care unit admissions were reported on February 7 in the United Kingdom, Greece, and Israel, according to a pooled analysis based on a literature search.
Case report from Japan of a 50-year-old man admitted 10 days after receiving the second dose of Pfizer’s vaccine. Shock and heart failure occurred.
A previously healthy 26-year-old man passed out while eating after receiving the first dose of Pfizer’s vaccine on February 9.
According to an FDA editorial, “the societal benefit of mass vaccination is overwhelming.”
On February 11, a previously healthy 20-year-old man was admitted after receiving the second dose of Moderna’s vaccine.
Report from the United States of an 18-year-old male hospitalized with myocarditis following COVID-19 vaccination.
A 69-year-old female in the United States developed pericarditis after receiving a Moderna booster on February 12.
Case report of a 48-year-old woman who suffered shock and fulminant myocarditis after receiving the second dose of Moderna’s vaccine on February 13, Japan.
The autopsies of two young boys were examined in the United States on February 14. One death certificate listed myocarditis.
Germany Case series of four patients with acute myocarditis/pericarditis after mRNA vaccination within 17 days. Researchers have concluded: “In view of its rarity and mild course, the risk-benefit ratio of vaccination remains positive compared to potential SARS-CoV-2 infection.”
On February 15, twenty-one patients in Canada were diagnosed with postvaccination myocarditis and at least one abnormality on cardiac MRI. In the short term, all were asymptomatic.
Case report of a 44-year-old male hospitalized after receiving the second dose of Moderna’s vaccine on February 16 in the United States, Illinois.
Feb. 17 Oman Report of a previously healthy 37-year-old man who was hospitalized for 16 days with myocarditis after receiving Pfizer’s vaccine.
A previously healthy 19-year-old from the United States was hospitalized with myocarditis after receiving the COVID-19 vaccine.
On February 18, a 24-year-old man was hospitalized with myocarditis shortly after receiving his first Moderna dose. A three-month follow-up revealed no abnormalities.
Report from Japan of a 77-year-old man who suffered from shock. 64 days after vaccination, I was discharged.
A 24-year-old man was hospitalized in Spain on February 21 after receiving his third dose of Pfizer’s vaccine. Other possible causes have been ruled out.
On February 22, Italy, three deaths were determined to be caused by myocarditis following vaccination.
Feb. 23 Singapore An analysis of reported myocarditis and pericarditis cases found a total of 34 cases out of 7.1 million doses administered as of the end of July 2021.
Austria and Germany: A series of young males who received heart failure therapy after being vaccinated with Pfizer.
Singapore, February 25 – A review of the literature reveals two to five cases of myocarditis per million vaccine doses.
Between March 10 and October 18, 2021, there were 22.1 cases per 100,000 doses in Hong Kong among adolescents who received at least one dose of Pfizer’s vaccine.
March 2022
Italy, March 1st, and so on. Imaging of 27 patients with suspected heart inflammation after COVID-19 vaccination reveals late gadolinium enhancement (LGE), which corresponds to myocarditis criteria.
Retrospective study of two emergency departments in South Korea finds myocarditis diagnosed in four males (17 to 49) between June 1, 2021 and October 15, 2021.
Between July 13 and November 2021, four patients were diagnosed with myocarditis within 21 days of receiving Pfizer’s third shot. March 5th, Japan: A 45-year-old woman was hospitalized with acute myocarditis after receiving her second dose of Moderna’s vaccine.
A previously healthy 21-year-old male was hospitalized after receiving Pfizer’s vaccine. Doctors: “Since our patient had positive serology for COVID-19 infection, the vaccination in combination with previous infection may have coalesced as trigger for the post-infectious cytokine-mediated hyper-inflammatory process typically seen in MIS-A.”
March 7, Italy A series of 20- and 21-year-old males with no prior medical history who experienced chest pain three days after receiving their second Moderna dose. Acute myopericarditis was confirmed by imaging.
On March 8, Germany, a 21-year-old man was hospitalized two days after receiving his second Pfizer dose. Finally recovered.
According to the article, “no deaths from myocarditis following mRNA COVID-19 vaccination have been reported in the United States.”
The benefits outweigh the risks for all age groups, according to a review published on March 9 in the Netherlands and the United Kingdom.
After excluding two cases due to “reasonable alternative diagnoses,” a March 10 Israel study of nationwide data identifies 15 cases in children aged 12 to 15 after Pfizer vaccination between June 2 and October 20, 2021.
Germany Imaging of myocarditis patients following COVID-19 vaccination.
Imaging report from an adolescent male hospitalized after receiving Pfizer’s vaccine in Canada and Chile.
March 11, Sweden Case report of a 20-year-old hospitalized after receiving a second dose of Moderna.
A previously healthy 45-year-old woman was hospitalized one week after receiving her first Moderna shot, according to a March 14 Canada report.
March 15, Poland Five teenagers who developed myocarditis after receiving COVID-19 vaccination. A 106-day follow-up revealed “persistent myocardium injury features.”
The American College of Cardiology issued guidelines for diagnosing and treating postvaccination myocarditis on March 16.
Three patients in Italy developed myocarditis as a result of Pfizer vaccination.
March 18, Japan A 17-year-old boy with a history of myocarditis was hospitalized for 23 days after receiving his second Pfizer dose.
Italy: A previously healthy 30-year-old man was admitted to the hospital with myocarditis after receiving Pfizer’s vaccine.
March 20 South Korea A 48-year-old woman required a heart transplant after being immunized with AstraZeneca and Pfizer vaccines. An organ autopsy revealed giant cell myocarditis, which was “possibly related to the vaccines.”
March 21, Ireland, and so on. According to a review of the literature, causality has not been established.
Hong Kong health records analysis revealed 38 cases of myocarditis following Pfizer vaccination.
Even after estimating 601 myocarditis cases per million among males aged 12 to 15, the United States claims that the benefits outweigh the risks.
The March 22 edition of Greece Review examines the similarities between postvaccination and hypersensitivity myocarditis.
Six months after Pfizer myocarditis, Israel Imaging finds evidence of residual scarring.
According to the Japan Review, postvaccination myocarditis is less common than post-COVID-19 myocarditis.
Within 12 weeks of COVID-19 vaccination, there were 105 deaths from cardiac-related causes in people aged 12 to 29 in the United Kingdom.
March 25th, US Case series of 16 children admitted to Seattle Children’s Hospital with chest pain and elevated troponin levels between April 1, 2021 and January 7, 2022, all within one week of receiving Pfizer’s vaccine. Imaging findings that lasted up to eight months.
From January 2020 to mid-2021, four COVID-19 patients developed myopericarditis, compared to 42 within 14 days of vaccination, according to a Hong Kong study.
Japan Case report of a previously healthy 13-year-old male hospitalized after receiving a Pfizer vaccination who was unable to sleep due to severe chest pain.
Experts in the United States have spoken out against the vaccination of healthy children with COVID-19.
March 28 Japan Detailed description of the Japanese health council’s monitoring of myocarditis.
Follow-up cardiac MRIs for seven patients hospitalized with myocarditis in the United States reveal some LGE that has not resolved, indicating heart scarring.
March 29th, Korea A 63-year-old woman died after receiving a second dose of AstraZeneca’s vaccine.
On March 30, an 84-year-old male was hospitalized after receiving Pfizer’s vaccine.
Chilean child develops myocarditis following COVID-19 vaccination.
March 31, Spain A 62-year-old woman was hospitalized after receiving her third dose of Moderna’s vaccine. Eventually released.
April 2022
According to a review of the literature, the majority of patients recover at least partially, with chest pain and fever being the most common symptoms.
The CDC analyzed data from 40 health care systems on cardiac complications following vaccination or infection on April 1.
4 April Singapore Case report of a woman who developed myocarditis after receiving a Pfizer vaccination.
A 59-year-old man in Japan developed pericarditis after receiving COVID-19 vaccination.
Egypt, April 5th, and so on. According to a review of the literature, a combination of intravenous immunoglobulins and corticosteroids may be an effective treatment, particularly in severe cases.
Grenada Case report of myopericarditis following COVID-19 vaccination in a 25-year-old man.
A 16-year-old male was admitted to the hospital with chest pain 48 hours after receiving the second dose of Pfizer’s vaccine. Researchers said: “This case demonstrates the rapid recovery with no sequelae following this adverse effect, highlighting that the benefits of the COVID-19 vaccination most likely outweigh the risks.”
Clinical review guide for Australia.
On April 7, Portugal, a 32-year-old male was hospitalized after receiving his second dose of mRNA vaccine.
Four people aged 18 to 42 were hospitalized with myocarditis after receiving COVID-19 vaccination on April 8, Germany.
Israel reports severe myocarditis following a Pfizer booster.
Patients in the United States were hospitalized on April 11 with symptomatic myocarditis following COVID-19 vaccination.
Singapore meta-analysis of reported cases of postvaccination myocarditis.
Turkey A 57-year-old female developed myocarditis as a result of Pfizer’s vaccine.
Five people had myocarditis or pericarditis after receiving three doses of an mRNA vaccine from Mayo Clinic Enterprise on April 14.
In New Zealand, two 12-year-old brothers were hospitalized with myocarditis after receiving second doses of Pfizer’s vaccine. Normalization during the follow-up.
Case report from the United States on April 15 of a 48-year-old male who experienced chest pain after receiving the second dose of Moderna’s vaccine.
Iran: A previously healthy 32-year-old female presented with myocarditis after receiving the first dose of AstraZeneca’s vaccine.
The Israel Study found no increased risk of pericarditis or myocarditis in adult COVID-19 patients.
According to a review of the literature, postvaccination myocarditis is “mild and self-limiting,” but “long-term evidence is lacking.”
Case report from Qatar of a previously healthy 22-year-old male hospitalized after receiving the second dose of Moderna’s vaccine.
Biopsy confirmed case of 63-year-old man hospitalized several weeks after Pfizer vaccination on April 19 in the United States. Doctors: “Given the limited data, there are no COVID-19 vaccination guidelines in patients with myocarditis, although the authors suggest avoidance in life-threatening cases.”
Report of a 27-year-old male in the UAE on April 20 following a second Pfizer dose.
A Nordic Study examining data from Denmark, Finland, Norway, and Sweden discovered that people who received COVID-19 vaccines had higher rates of heart inflammation than those who did not.
Taiwan, April 21 – A previously healthy 44-year-old female hairdresser was hospitalized with “stabbing chest pain” after receiving AstraZeneca’s vaccine. Doctors: “Vaccine-related myocarditis was highly suspected. Currently there is no established test to confirm the causal relationship.”
Seven patients in Iraq developed myocarditis after receiving mRNA vaccination. All of my symptoms went away.
In Israel, there were 195 cases of postvaccination myocarditis among people aged 12 and up.
According to a literature review published on April 22 in the United States, more studies are “needed to better evaluate risk factors and long-term outcomes of COVID-19 mRNA vaccine myocarditis.”
April 25, Canada A 49-year-old woman was hospitalized six days after receiving a Pfizer dose, which was followed by an AstraZeneca dose. I had a heart attack and an acute kidney injury. Non-vaccine causes have been ruled out.
A 19-year-old male with asthma was hospitalized after receiving the first dose of Moderna’s vaccine.
South Korea: A 17-year-old boy develops myocarditis after receiving his first dose of Pfizer’s vaccine.
Italy VAERS report analysis.
A 25-year-old man in the United States developed severe myocarditis following vaccination.
According to the FDA’s risk-benefit modeling, the risks still outweigh the benefits in the worst-case scenario, but the vaccines will cause 98 to 186 myocarditis cases per million doses in males aged 16 or 17.
Report from Japan of a 17-year-old previously healthy male whose myocarditis was still visible on cardiac MRI.
A 23-year-old male was hospitalized after receiving his second Moderna dose on April 27 in Germany. A three-month follow-up cardiac MRI revealed some irregularities.
Four patients in Japan were diagnosed with myocarditis after receiving mRNA vaccination.
LGE is still present in 80 percent of patients after follow-up MRIs on 15 patients on April 28 in the United States. Researchers suggest: “Follow-up CMR 6-12 months after acute episode should be considered to better understand the long-term cardiac risks.”
Emergency cardiovascular events in Israelis under the age of 40 increased during the rollout of the COVID-19 vaccine.
May 2022
South Korea reported a 22-year-old man with postvaccination myocarditis on May 1.
On May 3, a prospective study in Germany photographed 41 volunteers aged 18 to 50 before and after a third shot. One patient had subclinical pericarditis.
In the United States, a 57-year-old man with a history of COVID-19 develops myocarditis following vaccination.
Follow-up imaging in 13 patients in Canada revealed persistent LGE, “likely reflecting myocardial fibrosis.”
May 5, Malaysia Case report of a 24-year-old man who experienced days of chest pain about nine weeks after receiving his second Pfizer vaccine dose. Myocarditis has been diagnosed.
According to Canada Review, most patients’ symptoms resolve within three weeks.
May 7, Pennsylvania Case report of an 18-year-old male with prior infection who developed myocarditis after receiving Moderna’s vaccination.
On May 8, a 64-year-old man in the United States was diagnosed with postvaccination hemorrhagic pleuropericarditis.
May 9 South Korea According to VAERS analysis, the risk of severe adverse events such as myocarditis after COVID-19 vaccination was 6.85 per 100,000 vaccinated individuals.
10 May South Korea Case series of 40 adolescents with myocarditis following COVID-19 vaccination.
May 11 US At one to four months’ followup, nine myocarditis patients were asymptomatic, but two reported chest discomfort and cardiac MRI results that had not fully improved.
May 13, Japan Case report of a 41-year-old man who developed acute myocarditis after receiving a Pfizer vaccination.
The Japan Series, published on May 15, describes the biopsy results of four patients with clinically suspected myocarditis following COVID-19 vaccination.
Pericarditis after COVID-19 vaccination in Japan.
A 55-year-old woman was hospitalized in Thailand on May 17 after receiving AstraZeneca’s vaccine.
A 88-year-old female from Japan has postvaccination pericarditis.
May 18, Italy Case report of a 27-year-old man who developed recurrent myocarditis after receiving a Pfizer vaccine. Scientists concur: “In this case, the risk-benefit ratio is very balanced, and it is really difficult to determine which side it hangs the most.”
Report from South Korea of a 38-year-old woman with biopsy-confirmed myocarditis following COVID-19 vaccination.
Three young patients in Japan experienced severe chest pain following COVID-19 vaccination.
May 19 Egypt A systematic review of cases concludes that myocarditis is temporally linked to mRNA vaccines.
May 21: In the United States, a 74-year-old male was hospitalized after receiving a second dose of Pfizer’s vaccine. Later, he was readmitted to the hospital.
On May 23, Michigan received a report of a 30-year-old man who had previously been infected with COVID-19.
May 24 Greece Epidemiology of myocarditis review.
May 25th, UK A review of reported cases from the United Kingdom, the United States, and Europe.
Iran Review examines cardiac MRI findings in patients with myocarditis.
May 26th, Japan Case report of a 69-year-old man who died of heart failure after receiving the first dose of Pfizer’s vaccine.
May 27 Iraq, UAE According to reports, “only three patients died.”
May 28 Australia Cases, risk factors, and treatment strategies are reviewed.
Germany Report of 29-year-old hospitalized with myocarditis after receiving AstraZeneca’s vaccine three days prior.
June 2022
June 1 Canada Rate of postvaccination myocarditis higher among Moderna recipients when compared to Pfizer recipients.
US, South Korea Review of case reports finds 1.1 percent reported mortality.
June 2 Germany, etc. Eight patients between 13 and 56 vaccinated with an mRNA dose between January and August 2021 who developed cardiac side effects.
June 3 New Jersey Report of 45-year-old male hospitalized after Moderna vaccination.
Canada, Iran Review of studies claims postvaccination myocarditis cases “resolved entirely.”
June 6 US Review of clinical presentations and treatment.
June 11 US Comparison of cardiac MRI results from patients with postvaccination myocarditis and patients with myocarditis from other causes finds signs the latter are more serious.
June 10 South Korea Analysis of adverse event reports finds 74 suspected cases of myocarditis/pericarditis in 12- to 17-year-olds from March 5, 2021, to Feb. 13, 2022.
June 11 US (FDA) Four hundred eleven myocarditis cases in health claims database within seven days of COVID-19 vaccination. Increased risk among men aged 18 to 25. Researchers: “Our study results, along with the benefit–risk profile, continue to support vaccination using either of the two mRNA vaccines.”
June 12 Greece Two men hospitalized after mRNA vaccination.
Spain Two cases of pericarditis reported by same group that reported the first case report of myocarditis in the world.
June 13 US (Veterans Affairs) One hundred twenty-eight cases of myocarditis or pericarditis after mRNA vaccination in cohort of 433,672 U.S. veterans.
June 14 Australia Three patients with myocarditis or pericarditis after mRNA vaccination.
June 15 India Case report of young man with myocarditis after Covaxin vaccination.
Japan Report of 76-year-old woman with myocarditis following third Pfizer dose.
June 16 US Review of studies among athletes says myocarditis after COVID-19 infection higher than after COVID-19 vaccination, citing data from before June 2021.
June 21 Hong Kong Twenty-one heart failure events after Pfizer vaccination and 54 after CoronaVac vaccination, and 21 sudden deaths, among people with at least one dose from Feb. 23, 2021, to Sept. 9, 2021.
Japan Case report of postvaccination myocarditis. MRI performed six months later showed lingering abnormalities.
June 22 Germany Case series of 14 people who suffered biopsy-confirmed myocarditis after COVID-19 vaccination. Two had to be resuscitated before admission to the intensive care unit. Researchers: “The present case series reveal that cMRI was able to detect myocardial inflammation in only 33.3% (2/6) of the cases. Thus, EMB remains the definite standard in the diagnosis of viral and inflammatory cardiomyopathy.”
June 24 US, China Analysis of VAERS data finds myocarditis reports rare.
US (CDC) Editorial says available evidence “supports an association between mRNA COVID-19 vaccination and myocarditis or pericarditis.”
June 23 US Literature review of COVID-19 and vaccination effects in athletes.
June 22 Malaysia No increased risk for myocarditis after COVID-19 vaccination, analysis of national data finds.
June 25 France Nationwide review identifies 876 postvaccination pericarditis and myocarditis cases from May 12, 2021, to Oct. 31, 2021, with higher rates after Moderna vaccination. One case per 5,900 Moderna second doses among males aged 18 to 24.
June 26 Thailand Review suggests deferring second doses in people with myocarditis or pericarditis after first dose “until further safety data become available.”
Thailand Case report of 31-year-old hospitalized with myocarditis after AstraZeneca vaccination.
June 27 Italy Review examines impact of vaccination schedule.
June 28 Australia Seventy-five confirmed myocarditis cases in 12- to 17-year-olds as of Feb. 22, 2022.
June 29 US Severe case reported in previously healthy man after third dose of a COVID-19 vaccine.
June 30 US Case report review concludes severity of myocarditis worse among adults.
July 2022
July 1 Greece VAERS review finds peak myocarditis occurrence one to three days after COVID-19 vaccination; peak for pericarditis 15 to 30 days after vaccination.
July 2 Middle East, China Review of large-scale surveillance studies of Pfizer’s vaccine finds myocarditis is “consistently associated” with the shot.
July 3 Japan A 27-year-old man became unconscious during sports practice eight days after Moderna vaccination, and died 28 days later. A biopsy performed before death showed no evidence of myocarditis but an autopsy revealed “obvious severe myocardial inflammation findings, leading to the diagnosis of myocarditis.”
July 4 Japan Prospective study of health care workers receiving a COVID-19 vaccine booster identifies two cases of myocarditis among 3,821 subjects.
US Case report of 23-year-old man who experienced myocarditis in 2017 and experienced it again after second dose of Pfizer vaccination. Researchers: “We suspect the etiology of his recurrent myocarditis was incited by his Pfizer-BioNTech SARS-CoV-2 vaccination”
July 5 Turkey, etc. Literature review notes myocarditis “is considered as a common cause of sudden cardiac death.”
July 7 US A 45-year-old man with chest discomfort after COVID-19 experiences recurrence of symptoms after first COVID-19 vaccine dose. Admitted to the hospital after second dose with MRI-confirmed myocarditis.
July 8 Canada Two children with MIS-V within six weeks of Pfizer vaccination. COVID-19 testing came back negative.
Japan Review examines possible mechanisms of COVID-19-vaccination-related myocarditis and other hypersensitivity reactions.
Italy Literature review concludes benefits of vaccination “appear” to outweigh risk of myocarditis.
Japan A 32-year-old with fulminant myocarditis five days after first dose of Moderna’s vaccine. Researchers: “The mechanism of COVID-19 vaccine-associated myocarditis needs to be urgently investigated.”
July 9 Japan Patient with myocarditis following third dose of Moderna’s vaccine.
July 11 Germany Case report of 32-year-old man hospitalized after receiving Pfizer vaccination who went on to receive additional doses “which were tolerated under ongoing immunosuppressive therapy without any notable adverse events or heart failure aggravation.”
Taiwan Review concludes benefits of vaccination outweigh risks for children.
US Case report of young male hospitalized with myocarditis after Covaxin vaccination.
July 13 Canada Review calls for prospective studies.
US Analysis of Cleveland Clinic records show one in 34 patients with history of myocarditis experienced a recurrent case after two doses of mRNA.
Australia Record review identifies 33 patients aged 12 to 18 who presented with myocarditis to Monash Children’s Hospital between Aug. 1 to Dec. 31, 2021.
Denmark Cohort study finds nearly 100 myocarditis or pericarditis cases.
July 14 India Review of myocarditis cases in previously healthy individuals.
Germany Analysis of patients imaged with myocarditis symptoms after infection or vaccination.
US (CDC) Forty-five myocarditis events reported in children 5 to 11, some verified, during first four months of Pfizer vaccine administration to the age group.
July 15 Bangladesh Case report of 15-year-old female hospitalized one day after receiving second dose of Pfizer’s vaccine. Became unconscious but eventually improved.
July 16 US Review calls for standard criteria for using cardiac MRIs to diagnose myocarditis in children.
July 18 Italy Patients with resolved myocarditis received COVID-19 vaccine doses with no apparent recurrence, though no imaging was performed.
July 19 South Korea Report of a 16-year-old girl treated for three months for postvaccination myocarditis.
Turkey Two intern doctors experience vaccine-induced myocarditis in the same shift.
July 20 Germany Review calls for autopsies of deaths following vaccination.
India Cohort study from one hospital from July 2021 to December 2021 identifies one postvaccination case.
Qatar Review of six studies from 2021 finds some children experienced chest pain with postvaccination myocarditis.
Hong Kong Review finds symptoms quickly resolve in most cases.
US Kaiser Permanente study of adults who received up to three doses between Dec. 14, 2020, and Feb. 28, 2022, and were diagnosed with myocarditis within 21 days identifies 41 cases. One death (attributed to cancer).
July 25 US Review comparing benefits and risks.
New Zealand Case report of 18-year-old who was awoken 15 hours after second Pfizer dose and admitted to hospital with pericarditis. Patient did not appear for three-month followup cardiac MRI.
US No persistent symptoms at a median of 159 days in six myocarditis patients with median age of 16.
July 26 Denmark Among children 5 to 11, between Nov. 25, 2021, and March 1, 2022, one case of myopericarditis was identified.
July 27 US Case report of 8-year-old with myocarditis after second COVID-19 vaccine dose.
July 28 Italy Four hundred forty-one people developed postvaccination myocarditis between Dec. 27, 2020, and Sept. 30, 2021.
South Korea, US Case report of 59-year-old man hospitalized after first dose of Pfizer vaccine.
UK Review of cases finds 94 percent were among males.
Spain Report of 72-year-old female with myocarditis after third Pfizer dose.
July 29 Israel Case series of all rheumatology centers in Israel finds nine 16- to 21 year-olds who developed myocarditis after second Pfizer dose.
July 30 Canada Myocarditis/pericarditis risk higher after Moderna’s shot compared to Pfizer’s shot.
August 2022
Malaysia
College of Paediatrics, Academy of Medicine of Malaysia statement (pdf).
Italy Case report of deferred postvaccination myocarditis.
Aug. 1 Japan A 60-year-old woman hospitalized after second dose of Pfizer’s vaccine. Discharged after three weeks.
Italy, Sweden Followup with transthoracic echocardiography with 28 patients identified some lingering problems. Researchers: “This case series shows a higher incidence of acute pericarditis in patients administered with COVID-19 vaccines than previously estimated, probably because of a more comprehensive assessment of clinical as well as echocardiographic parameters.”
Aug. 2 Germany Case report of 35-year-old man who suffered myocarditis after Pfizer vaccination and clozapine initiation.
Aug. 3 UK, etc. Review of clinical characteristics of myocarditis patients.
Aug. 4 Italy Incidence of MIS-C after COVID-19 infection higher than myocarditis after vaccination in Italian region from March 2020 to July 2022.
Japan Report of 18-year-old with postvaccination pericarditis.
Denmark Imaging of 10 young patients finds “normal to mildly impaired cardiac function.”
Aug. 5 US (CDC) Myocarditis and pericarditis cases recorded shortly after Novavax vaccination, “suggesting a possible causal relationship.”
Iran Report of 72-year-old male who developed symptoms of heart failure after receiving COVID-19 vaccine. Surgery to remove pericardium done.
Aug. 6 Canada Imaging study finds persistence of abnormal LGE beyond three months. Researchers: “Regional fibrosis following edema resolution was commonly observed, justifying need for ongoing surveillance.”
Aug. 8 Thailand (later peer-reviewed) Prospective study of 301 students at two schools in Thailand finds 29 percent of the youth, aged 13 to 18, experienced cardiovascular effects after Pfizer vaccination. Myopericarditis confirmed in one patient; six had suspected pericarditis or myocarditis.
US (Moderna) Three thousand, one hundred and seven reports of myocarditis after vaccination received from Dec. 18, 2020, to Feb. 15, 2022, in Moderna’s global safety database. Higher than expected rates in males aged 18 to 24.
Japan Case report of 14-year-old boy who suffered acute myocarditis after COVID-19 vaccination.
Aug. 9 Greece A 50-year-old man with acute myopericarditis after second Pfizer vaccination. COVID-19 testing came back negative. Discharged after six days. Post-six-month imaging showed signs “compatible with healed myocarditis.”
Aug. 10 US Case report of 16-year-old male hospitalized with chest pain.
Aug. 11 Brazil Theories on myocarditis and its outcomes, including sudden deaths.
Australia Risk-benefit model estimates benefits of COVID-19 vaccination outweigh risk of myocarditis.
Aug. 15 US Case report of a 63-year-old woman with myocarditis after mRNA vaccination.
China Review of cases among youth.
Aug. 17 Germany Of 44 patients with symptoms suggestive of perimyocarditis after COVID-19 vaccination, imaging confirmed diagnosis in 42.
Aug. 18 Japan Case series of five patients who presented with myocarditis within 3 days of a second Pfizer dose between June 2021 and January 2022.
Aug. 19 US (CDC) Moderna and Pfizer vaccines associated with increased risk of myocarditis and pericarditis in 18 to 39-year-olds.
US (CDC) No reports of myocarditis among children 5 to 11 between May 17 and July 31, 2022.
Japan Autopsy analysis of 54 deaths potentially caused by vaccine-related adverse effects finds 3 causally related to myocarditis.
Aug. 22 UK Case series of people aged 13 or older and vaccinated between Dec. 1, 2020, and Dec. 15, 2021, finds higher risk of myocarditis after Moderna second dose among men than from COVID. Identifies 100 deaths within 28 days of hospital admission from myocarditis.
Aug. 23 Germany Imaging from 10 vaccinated patients with myocarditis compared to 10 patients suffering from viral myocarditis. Researchers: “The observed imaging markers were closely related to regular viral myocarditis in our cohort.”
Aug. 24 Australia Report of a near-fatal case.
Aug. 25 Japan Report of a healthy 14-year-old male who experienced worsening chest pain after receiving Pfizer third dose. Symptoms eventually resolved.
South Korea Report of 30-year-old man with myopericarditis following Novavax vaccination.
Aug. 26 Brazil Report of 49-year-old female with pericarditis after Pfizer vaccination.
Japan Report of postvaccination myocarditis in 13-year-old twins.
April 27 US (CDC) Comparison finds outcomes of traditional myocarditis worse than myocarditis after COVID-19 vaccination.
Aug. 29 US, India Review compares myocarditis after COVID-19 vaccination and infection.
Aug. 30 Japan Autopsy report of a 61-year-old woman who died with severe myocarditis 10 days after receiving COVID-19 vaccine. COVID-19 testing came back negative.
Aug. 31 Italy After excluding people with previous COVID-19, analysis covers 24 patients admitted to single center for pericardial diseases following COVID-19 vaccination from April 1, 2021, to April 15, 2022.
September 2022
Sept. 1 Italy Thirteen patients who received COVID-19 vaccines despite history of myocarditis do not experience symptoms.
Qatar, UK Case series includes one patient with postvaccination myocarditis.
Sept. 2 Japan Report of 49-year-old man who needed mechanical circulatory support.
Sept. 5 Japan Report of postvaccination myocarditis in elderly woman following COVID-19 vaccination. Treated using steroid pulse therapy.
Sept. 6 China, US Review concludes that mRNA vaccines appear to be associated with pericarditis and myocarditis.
Israel Review of reports to Israeli Ministry of Health rom July 31, 2021 (first day of booster), through Nov. 5, 2021, finds 91 reported cases of myocarditis, including 35 within 30 days of booster vaccination. Myocarditis rates among males aged 16 to 19 were 64 per million boosters.
Sept. 7 South Korea Report of 38-year-old woman hospitalized five days after first Pfizer vaccination. Developed biventricular failure, cardiogenic shock and acute renal failure. Discharged after one month. MRI at six months showed persistent LGE.
Italy Inpatient records from University of L’Aquila identifies cases of pericarditis after mRNA vaccination.
China Case report of 36-year-old woman who died after ZF2001 vaccination. Autopsy requested by family due to temporal link to vaccination. Researchers: “Although potential cause of myocarditis due to viral infection cannot be completely excluded because no viral culture/viral DNA/RNA detection were performed, myocarditis could be a severe side effect of the protein subunit of COVID-19 vaccine.”
US Chronic pericarditis in 32-year-old athlete that may have been caused by COVID-19 vaccination.
Sept. 8 Japan Report of 15-year-old male hospitalized after second Pfizer dose with chest pain. Lingering LGE. Researchers: “Although post-COVID-19 vaccination myocarditis has a favorable prognosis and is considered curable, it may leave abnormalities in the myocardium, as observed in this case; it may therefore be premature to declare it as a complication with a good prognosis.”
Sept. 12 China Analysis of VAERS reports finds no increase in risks of myocarditis or pericarditis following a booster.
Sept. 13 Italy Report of 30-year-old man who did not respond to conventional therapy and was successfully treated with anakinra.
Sept. 14 Israel Seven patients received an initial and follow-up scan a median of 159 days later, with abnormal results remaining in some patients.
US Another followup, from 9 young males. Over a median followup of 146 days, none of the nine male patients experienced recurrent myocarditis, heart failure, or arrhythmias, or were readmitted to the hospital for any cause. Abnormal global longitudinal strain and persistent LGE found in most.
Sept. 20 Malaysia Review outlines guidance for autopsies of deaths after COVID-19 vaccination.
Sept. 21 CDC Follow-up surveillance study of cases reported to VAERS reliant on surveys finds 54 percent of patients with follow-up MRIs had abnormal findings such as swelling or scarring.
Sept. 23 China Researchers drew from experience of adverse events after Hepatitis B vaccination to provide insights into post-COVID-vaccination myocarditis.
Hong Kong Followup 60 to 180 days after initial diagnosis finds normal results on treadmill testing but significant weight increases and persistent symptoms.
Sept. 25 China, US Systematic review and meta-analysis finds elevated rate of myocarditis in pericarditis in vaccinated people.
Sept. 26 South Korea Analysis of blood from myocarditis patient.
Italy Report of 16-year-old male whose symptoms resolved.
Sept. 28 Qatar Report of severe myocarditis in 38-year-old female.
Israel Blood samples taken during and two to four days after fourth dose showed myocardial injury in two of 324 participants.
Sept. 29 Japan Man in his 90s who experienced heart failure after receiving third dose of Pfizer’s vaccine diagnosed with pericarditis after autopsy. Researchers: “Although a direct causal relationship between COVID-19 mRNA vaccination and pericarditis cannot be definitively established in the present case, no other causes were identified from the autopsy findings and laboratory results.”
Singapore Analysis of institution’s cohort finds five patients with heart failure, two with shock, three who were intubated, and one who died.
October 2022
US Report of 19-year-old with postvaccination myocarditis.
Oct. 1 Germany Report of a 76-year-old with history of Parkinson’s disease who died three weeks after second Pfizer dose (third dose total). He received the dose despite never fully recovering from side effects from first two doses. Researchers: “While the histopathological signs of myocarditis were comparatively mild, the encephalitis had resulted in significant multifocal necrosis and may well have contributed to the fatal outcome.”
Oct. 4 Saudi Arabia Case series of patients as young as 14 years old. One had persistent left ventricular dysfunction.
US (CDC) Verification of myocarditis and pericarditis cases within seven days of mRNA vaccination through VSD data finds incidence rates as high as 150.5 million after dose 2 in males 12 to 15 and 188 per million booster doses in males aged 16 or 17.
Oct. 5 Israel MRI of adolescents (age 12–15) with a clinical diagnosis of myocarditis within 42 days following a first COVID-19 vaccine dose were analyzed.
Oct. 6 Europe Statement from European Society of Cardiology says benefits still outweigh risks.
Oct. 10 Canada Report of recurrent myocarditis in 25-year-old man.
Italy Report of shock in myocarditis patient following COVID-19 booster.
Oct. 13 US Data from VAERS show three reported myocarditis cases among children in Delaware.
Oct. 14 South Korea Report of previously healthy 20-year-old man. Confirmed with endomyocardial biopsy.
Germany More myocarditis cases in Germany after COVID-19 vaccination than after COVID-19. Researchers: “We support the call for a comprehensive and careful benefit–risk evaluation of COVID-19 vaccines.”
Oct. 15 US Series of five adults, aged 18 to 34, hospitalized with myocarditis after COVID-19 vaccination. Followup found two with persistent symptoms.
US Comparison of 69-year-old male with myocarditis after Moderna vaccination and 46-year-old female with myocarditis after COVID-19.
Greece Report details case and speculates that myocarditis cases cross the blood-brain barrier.
Oct. 18 Japan COVID-19 vaccination was associated with higher risk of myocarditis death across all age groups, not only young adults.
Oct. 19 US Finding of “nearly identical alterations in gene expression that would predispose to inflammation, coagulopathy, and myocardial dysfunction” among patients with heart injury after vaccination and COVID-19.
Oct. 20 Germany, Israel Antibody analysis in patients with suspected myocarditis after COVID-19 vaccination. Many underwent biopsy.
Oct. 21 Singapore Series on patients with postvaccination myocarditis and active autoimmune rheumatic diseases.
Oct. 22 Australia Report of previously healthy man who developed severe severe dilated cardiomyopathy after Pfizer vaccination.
Oct. 26 US (FDA) Surveillance of outcomes in vaccinated people aged 12 to 64 finds myocarditis meets safety signal after Pfizer vaccination.
Oct. 30 Japan Analysis of documents published by Japanese health committee identifies 476 cases of postvaccination myocarditis between Feb. 17, 2021, and Nov. 14, 2021. Researchers: “Risks of myocarditis and pericarditis following SARS-CoV-2 mRNA vaccines in Japan seems to be significantly elevated for adolescent and young adult males.”
Oct. 31 Italy Series finds “persistent, although decreased, myocardial injury” in six of nine patients at 12-week followup. One still had symptoms.
November 2022
Taiwan Report of 23-year-old female with acute chest pain after first dose of Pfizer’s vaccine.
Nov. 1 Saudi Arabia Case report of 18-year-old hospitalized after receiving Moderna’s vaccine. Recovered after one day and discharged.
Nov. 2 Japan Report of previously healthy 13-year-old who suffered myocarditis and postural orthostatic tachycardia syndrome after COVID-19 vaccination.
Nov. 3 US (CDC) No myocarditis cases in group of 7,077 vaccinated children across Kaiser Permanente Southern California.
Nov. 4 Australia One death, 1,342 cases of myocarditis/pericarditis reported after COVID-19 vaccination in Australia.
Nov. 5 Germany Imaging study compares patients with myocarditis following COVID-19 vaccination to patients with traditional myocarditis and finds “demonstrated lower prevalence of LGE but higher prevalence of abnormal T1/T2 mapping.”
Nov. 8 China Cause of death for 59-year-old man determined to be viral myocarditis combined encephalitis from COVID-19 vaccination.
Nov. 9 Germany Follow-up study finds LGE visible in all patients and two with new symptoms. Researchers: “The long-term implications of the remaining myocardial scar-tissue after vaccine associated myocarditis remain unknown warranting further studies.”
Nov. 12 Italy Sixteen to 19-year-old males more likely to be harmed by Moderna’s vaccine, while the risk-benefit profile was favorable for all other age groups, cohort study in Lombardy Region concludes.
Nov. 15 New Zealand Review says most cases of post-vaccination myocarditis are mild.
US Report of 19-year-old man with myocarditis after Pfizer vaccination. Researchers: “Considering the protective effects of the COVID-19 vaccine against hospitalization and death, and the low incidence of vaccine-associated myocarditis, the overall benefits of the COVID-19 vaccine would outweigh the risks. However, it is unclear if the same rate of benefit is provided by the booster doses of the COVID-19 vaccine. Thus, the decision for booster doses should be individualized based on the risks versus benefits.”
Canada Rates of post-vaccination myocarditis higher after Moderna vaccination than after Pfizer vaccination, British Columbia cohort study finds.
Nov. 17 Egypt
Review posits cause of myocarditis is vaccines upregulating micro RNAs.

Nov. 18 Saudi Arabia Report of 48-year-old male hospitalized after receiving AstraZeneca’s vaccine. COVID-19 testing came back negative. At 39 days, all symptoms had resolved except for exertional dyspnea.
Israel Maccabi Healthcare Services analysis finds no myocarditis cases after second booster.
Nov. 21 Japan Case report of a 23-year-old male with post-vaccination myopericarditis hospitalized after receiving second Moderna dose. Researchers: “Although this episode was not fatal and there was no residual cardiac dysfunction, we advised the patient to avoid additional COVID-19 mRNA vaccines because of this episode.”
Canada British Columbia researchers identify 141 myocarditis cases within 21 days of COVID-19 vaccination from Dec. 15, 2020, to March 10, 2022, with the highest observed-to-expected ratio seen after a second dose among males aged 18–29 years who received Moderna’s vaccine (148.32 per 100,000).
South Korea Report of a previously healthy 17-year-old female hospitalized with chest pain three days after first Pfizer dose. After discharge, she passed out at a restaurant. Admitted to ICU. Later discharged again. Doctors found her cardiac function “did not fully recover” in followup.
Nov. 22 Singapore Myocarditis erroneously diagnosed in one case.
Nov. 23 Japan Report of previously healthy 51-year-old woman hospitalized after second dose of Moderna’s vaccine. She suffered organ damage and other issues. Discharged after two weeks. Followup showed she was “clinically well.” Described as possible MIS-V.
Japan Case report of 19-year-old man with heart failure.
Morocco A 23-year-old with heart problems after BIBP COVID-19 vaccination.
Nov. 24 Europe Cohort study pulling from five European databases from Jan. 1, 2020, to Dec. 31, 2021, identified background rates and increased rates of myocarditis after Pfizer vaccination in adolescents aged 12 to 17, and statistically nonsignificant increases after Moderna’s vaccine.
Nov. 27 Germany: Autopsies performed at Heidelberg University Hospital on people who died unexpectedly within 20 days of a COVID-19 vaccination identified myocarditis in five people, with median age of 58. Other possible causes have been ruled out.
Nov. 28 Qatar Report of two cases of myocarditis in previously healthy young males after receiving Pfizer vaccination.
Nov. 29 US, etc. Review finds post-vaccination myocarditis most prevalent among young males and calls for prospective studies “to establish a concrete relationship between myocarditis and the COVID-19 vaccine.”
Nov. 30 Japan Case report of 64-year-old who received a second dose after experiencing myocarditis and did not show new symptoms.
December 2022
Dec. 5 US Risk-benefit analysis for booster mandates at universities estimates that to prevent one COVID-19 hospitalization over a six-month period, 31,207–42,836 young adults aged 18–29 years must receive a third mRNA vaccine. Per hospitalization prevented, estimated 18.5-plus serious adverse events caused, including 1.5–4.6 booster-associated myopericarditis cases in males.
Hong Kong, UK One death, two heart failures from myocarditis after Pfizer vaccination, but postvaccination myocarditis compares favorably to historical myocarditis, researchers say.
Dec. 13 Taiwan Symptoms resolved in all postvaccination patients aged 12 to 18 with cardiovascular symptoms at emergency department after Pfizer vaccination. Doctors did not follow up with most.
Dec. 16 US (CDC) Clusters of myocarditis cases after second Pfizer dose in people aged 12 to 39 in tree-based evaluation from VSD.
Dec. 22 France, Italy Series of men with acute myocarditis after COVID-19 vaccination.
Dec. 23 Australia Two young patients suffer myopericarditis after Pfizer vaccination, and again after Novavax vaccination. Both had persistent symptoms.
Dec. 28 US Review finds only one in four articles on postvaccination myocarditis used four stratifiers, and men younger than 40 receiving a second dose of an mRNA vaccine are at greatest risk.
Turkey LGE present in seven of seven patients three to six months later; myocardial edema persistent in two.
January 2023
Jan. 3 Qatar High probability that some deaths after COVID-19 vaccination related to vaccination, researchers say.
Jan. 4 US Analysis of blood finds “unbound” spike protein in plasma of people with myocarditis after vaccination.
Belgium Case report of 55-year-old man who suffered myocarditis and other problems after receiving Moderna’s booster.
Jan. 5 Taiwan Seventeen percent of high school students reported cardiac symptoms after second Pfizer dose in prospective study. Abnormal electrocardiogram results in one percent.
Portugal Portuguese Society of Cardiology says “unequivocal” evidence of link between COVID-19 vaccines and myocarditis
Palestine One case of myocarditis reported in survey at university.
Jan. 9 UK, Germany Imaging study of children who presented at institutions between July 2021 and August 2022 with signs of acute myocarditis after receiving Pfizer vaccines finds signs of heart scarring.
Italy Death “from COVID-19” in a person who was fully vaccinated.
Jan. 11 Japan Case report of 13-year-old with myocarditis after Pfizer vaccination.
Jan. 17 US Of 179 service members with prior vaccine-associated myocarditis who received COVID-19 vaccine, 11 developed symptoms within 30 days. All eventually recovered.
Saudi Arabia One report of myocarditis among 385 kids surveyed.
Jan. 18 Japan A 43-year-old man with myocarditis after Moderna booster.
Germany Case report of pericarditis following AstraZeneca vaccination.
Jan. 19 US A 17-year-old male with post-vaccination myocarditis still has chest discomfort six months later. Researchers: “The long-term outcomes of COVID-19 vaccine-associated myocarditis are unclear. This patient had nonsustained ventricular tachycardia over 6 months after diagnosis.”
Australia Differences between Brighton and CDC definitions of myocarditis.
Greece Case report of pericarditis in woman after AstraZeneca vaccination.
Jan. 23 Japan Meta-analysis of efficacy and safety among children aged 5 to 11 pegs myocarditis incidence at 1.8 cases per million second doses.
Jan. 26 South Korea Case report of myocarditis after receipt of MVC-COV1901 vaccination.
Jan. 27 Japan Autopsy of 71-year-old man who died after first Pfizer vaccination revealed myocarditis with extensive fibrosis. Researchers: “After reviewing previous reports on mRNA COVID-19 vaccine-associated myocarditis, it seemed likely that hypersensitivity myocarditis was caused by the BNT162b2 COVID-19 vaccine.”
Jan. 31 Libya, US Report of 34-year-old man with myocarditis after receiving Pfizer’s vaccine.
February 2023
Feb. 1 Nordic 530 people across Nordic countries suffered myocarditis related to COVID-19 vaccination, compared to 109 with COVID-associated myocarditis. Eight cases of heart failure or death among vaccinated 12- to 39-year-olds.
According to the Feb. 2 Italy Review, the majority of studies are from early variants rather than Omicron.
Brazil Case report of a 23-year-old man who developed heart scarring after his first Pfizer dose.
Case report of a man with postvaccination myocarditis, published in Japan on February 4th.
On February 8, a 29-year-old female from Iran was hospitalized three months after receiving her second dose of Sinopharm’s vaccine. COVID-19 is responsible for this. Spend 11 days in the hospital due to long-term issues.
Taiwan reported 204 cases of myocarditis/pericarditis following vaccination from March 22, 2021 to February 9, 2022.
Myocarditis after COVID-19 vaccination persisted for 12 months in Japan on February 10. Some of the patients died.
The India Review, published on February 14, calls for the harmonization of case definitions and the publication of treatment guidelines.
From January 2021 to November 2021, a surveillance network covering 99 counties recorded six cases of myocarditis and 134 cases of heart failure among fully vaccinated people.
Fifty-six reports of myocarditis or pericarditis following Novavax vaccination were reported to VigiBase in Spain and Venezuela.
Feb 20 – In the United States, a patient with postvaccination myocarditis is experiencing recurrent ventricular tachycardia. A cardioverter defibrillator was implanted by doctors.
Retrospective analysis of patients presenting to St Vincent’s Hospital in Sydney with suspected COVID-19 vaccine-related myocarditis and pericarditis identifies 10 cases, one of which has MIS-V.
On February 24, a case of myocarditis and encephalopathy occurred concurrently following vaccination in the United States.
In Israel, a 22-year-old man dies from pericarditis caused by a Pfizer vaccination.
On the 27th of February, a Canada Cohort analysis in Ontario discovered 77 children with myocarditis or pericarditis following Pfizer vaccination out of 1.6 million doses administered.
March 2023
On March 3, Germany, a 23-year-old male without COVID-19 was hospitalized following the second dose of Moderna’s vaccine. After eight days, I was released. At the follow-up, there were signs of damage. Researchers wrote: “Three months later the patient presented for a control examination. The patient reported to be without any complaints at rest but had not engaged in more intense physical exertion so far. Electrocardiographic findings were reduced, but still detectable.”
According to the March 6 Italy Review, COVID-19 vaccinations may be linked to increased blood pressure.
March 7, France A review of the French safety system reveals a signal for COVID-19 vaccines and myocarditis in June 2021.
At a two-month follow-up, a Canadian Prospective study finds persistent heart inflammation in two of 17 patients and LGE in 11 of 17 patients.
Fifty-seven percent of 21 patients with suspected myocarditis after COVID-19 vaccination met updated Lake Louise criteria for myocarditis on March 10, Austria, Italy.
According to the March 11 issue of the US Review, myocarditis “remains a recognized cause of sudden cardiac death in children and athletes.”
Spain Information on diagnosing and treating postvaccination myocarditis.
March 13 – In the United States, interest in myocarditis was low until COVID-19 vaccines were introduced, according to an analysis of search results and reports.
Italy A short-term follow-up revealed that inflammation persisted in nearly a quarter of the cohort.
Case report of a 72-year-old woman with myocarditis and heart failure following COVID-19 vaccination on March 15, Hong Kong.
A 14-year-old girl “died unexpectedly” two days after receiving her third Pfizer dose on March 20 in Japan. Doctors: “The cause of death was vaccine-related myopericarditis, which led to severe arrhythmias and progressive heart failure.”
Heart failure and Still’s disease in an elderly woman in Hong Kong following COVID-19 vaccination.
On March 24, Canada, the rate of myocarditis cases per million within seven days of vaccination was 17.9 after the second dose and 6.4 after the booster dose. Males aged 18 to 29 had the highest rate of 225 per million second Moderna doses. In the same population, the highest booster rate was 39 per million.
March 25 Hong Kong Risks of myocarditis and pericarditis increased following Pfizer vaccination, including after the third dose.
Researchers in England discovered no significant increase in cardiac or all-cause mortality within 12 weeks of COVID-19 vaccination compared to more than 12 weeks after any dose, but they did discover an increase in cardiac death in women after a first dose of non-mRNA vaccines.
At the one-year followup, three of four patients had completely resolved their symptoms. The patient who remained “was lost to follow up after hospitalization.”
The VAERS analysis in Italy uncovers over 5,200 reports of post-vaccination myocarditis and over 3,500 reports of post-vaccination pericarditis.
Based on reported cases, Thailand has 0.97 myocarditis cases per 100,000 doses administered, with 10 deaths.
March 29: One case of acute pericarditis and one case of acute myocarditis in 15-year-old males is reported in Spain.
April 2023
Retrospective imaging review finds impact on myocardial strain “less significant” in post-vaccination cases compared to traditional cases on April 1 in the United States.
Case report from the United States of myopericarditis caused by a Pfizer booster. After seven days, the patient was discharged.
Two patients in Indonesia required mitral valve surgery after developing myocarditis following COVID-19 vaccination.
Hong Kong’s extended primary series interval reduced the occurrence of myocarditis. On April 4, Spain, a 28-year-old male developed postvaccination acute myocarditis.
April 5 South Korea Records from the Korea Immunization Management System show 173 cases of myocarditis among adolescents between July 19, 2021 and September 30, 2022.
On April 7, Italy, a group of 26- and 27-year-old men were hospitalized after receiving Pfizer booster shots. Discharged after a few days and appeared to be recovered at four-week follow-up exams.
April 15, Australia: Twenty-nine cases of definite or probable myocarditis at a Melbourne children’s hospital after vaccination, compared to five after COVID-19.
Malaysia 87 myocarditis cases were identified within 21 days of vaccination between February 1, 2021 and February 28, 2022.
April 17, Switzerland A patient with postvaccination myocarditis received a second dose with no complications after taking colchicine as a preventative measure.
According to the April 18 Germany, Japan Review, there is inconclusive evidence for myocarditis in children aged 5 to 11.
April 19, Spain Two patients with fulminant myocarditis following mRNA vaccination.
One year of safety surveillance includes 570 confirmed post-vaccination myocarditis cases, according to the CDC and FDA on April 21. The majority of the 36 reported deaths had other causes, and the rest had “insufficient information.”
Analysis of EudraVigilance database reports conducted on April 22 in the United States reveals an increased risk of myocarditis.
April 24, Denmark One and a half deaths from cardiovascular disease are estimated for every COVID-19 death avoided by mRNA vaccination.
May 2023
According to the May 1 US Review, as of February 2023, the literature contained descriptions of 14 deaths involving autopsy-proven myocarditis.
May 5th, US Immune system reactions in myopericarditis patients.
Alternative causes of death should be considered before concluding that vaccination was the cause of death, according to an Austrian doctor.
Australia, May 8: Report of triplets with myocarditis following Pfizer vaccination.
Case report of biopsy-confirmed eosinophilic myocarditis in a 24-year-old male following COVID-19 vaccination in the United States. “
May 9 CDC One case of myocarditis in pregnant women following booster.
May 10 US Some postvaccination myocarditis patients had persistent LGE in followup, despite the absence of active inflammation.
May 11: A review of myocarditis case rates and presentation in the United States.
In Sweden, 96% of registered cases were confirmed to be myocarditis.
May 15th, Italy Imaging results from cases of postvaccination myocarditis.
According to a May 17 Europe, etc. review, myocarditis following COVID-19 vaccination “is rare and almost always of a benign nature.”
The Veterans Health Administration identified 178 potential cases of post-vaccination myocarditis, with 20% of cases confirmed through chart review.
May 18, Japan Case report of an 81-year-old man who had heart failure 9 years prior and experienced heart failure again after receiving COVID-19 vaccination.
Thailand Report of a 13-year-old who achieved normalcy after a six-month follow-up.
Researchers: “The policy was highly successful in the reduction of carditis, but the trade-off is the potential cost of missed opportunities to benefit from the vaccine and, to a lesser extent, population-level immunity.” May 19 Canada Benefit-risk assessment focused on Hong Kong’s single dose policy.
Researchers: “Further research is needed to better understand the long-term implications of pericarditis and myocarditis following COVID-19 vaccination with this vaccine and to develop strategies to minimize the risk of these complications during anesthesia.” US Report of man with postvaccination pericarditis who received anesthesia for fluid drain.
May 22 FDA issued a safety alert for myocarditis and pericarditis in children aged 5 to 17.
A meta-analysis of 12 to 17-year-olds in China finds 43.5 myocarditis cases per million doses, rising to 107.7 cases per million second doses in males.
May 24 Taiwan Of 681 children who complained of chest pain after receiving a Pfizer vaccination, 29 were diagnosed with myocarditis, pericarditis, or both; none died.
May 27, Italy – Two children with myocarditis following vaccination developed “persistent lesions” and were readmitted months later.
Pericarditis in Taiwan after a bivalent mRNA dose on May 29.
June 2023
June 1 Switzerland Case report of a man in his 40s who developed myocarditis after receiving Moderna vaccination; symptoms resolved “rapidly.”
South Korea, June 2 – An examination of 480 cases of COVID-19 vaccination-related myocarditis, including 21 deaths, reveals eight sudden deaths due to myocarditis.
In all scenarios, the FDA Benefit-risk Assessment estimates that more COVID-19 hospitalizations will be avoided than myocarditis cases will be caused.
On June 3, Turkey, a case of postvaccination myocarditis was reported.
Researchers: “For both mRNA vaccines, elevated risks were found in those under 40 years old, predominantly in males, were highest after the second priming dose, and were generally lower in those vaccinated after a prior SARS-CoV-2 infection.” June 7 UK Between Feb. 22, 2021, and Feb. 6, 2022, 486 patients with postvaccination myocarditis in the 16 to 39 age group. Another 823 cases among those 40 and older.
On June 8, Italy, a cohort study in the Lombardy region found 122 myocarditis cases and 304 pericarditis cases within 28 days of COVID-19 vaccination.
A single-center imaging study conducted in the United States on June 9 discovered that left ventricular longitudinal strain improved over time following postvaccination myocarditis.
June 13 Korea There were 511 cases of myocarditis reported after vaccination between February 26, 2021 and June 4, 2022, with five fatalities.
Fifty-two verified reports of myopericarditis in adults following Johnson & Johnson vaccination were received by the FDA and the CDC on June 14.
FDA and CMS report nearly 1,300 cases of myocarditis and pericarditis among Medicare beneficiaries aged 65 and older following booster vaccination, with no increased risk.
Based on imaging, post-vaccination myocarditis in Spain is similar to other myocarditis cases.
June 20 Israel There were no cases of myocarditis following the bivalent booster.
Data from 29 centers from August 1, 2021, to March 10, 2022, identified 139 cases of postvaccination myocarditis, with 1.4 percent of patients dying after a three-month followup.
July 2023
July 1: Cases of postvaccination myocarditis in the United States are more likely to be milder than COVID-19 myocarditis, according to a review. July 3: A review in Indonesia describes postvaccination myocarditis as “relatively benign, with a median length of hospitalization of 5 days, intensive care unit admission of 12%, and mortality of 2%.”
July 7th, Australia: Three sets of siblings, including two sets of twins, experience chest pain after receiving the COVID-19 vaccination, and five are diagnosed with myocarditis.
A prospective study found lower white blood cell counts and platelet concentrations.
July 20 Italy Of the 460 athletes who responded to the survey, none reported myocarditis following vaccination.
July 25 Denmark 31 cases of myocarditis and pericarditis found after bivalent mRNA booster.
Some patients still have problems one year later, according to a follow-up study.
August 20, 2023
On August 9, New Zealand researchers discovered a statistically significant link between Pfizer vaccination and myocarditis/pericarditis.
On August 10, Bangladesh, a patient with chest pain following COVID-19 vaccination was diagnosed with takotsubo cardiomyopathy.
On August 22, Italy, VAERS received reports of 566 cases of myocarditis following bivalent vaccination.
Aug. 24 Canada Imaging of postvaccination myocarditis is similar to other types of myocarditis, but less severe.